{"id":55769,"date":"2022-05-20T11:04:16","date_gmt":"2022-05-20T11:04:16","guid":{"rendered":"https:\/\/www.mymsd.ch\/fr\/?p=55769"},"modified":"2025-11-23T18:41:57","modified_gmt":"2025-11-23T18:41:57","slug":"keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance","status":"publish","type":"post","link":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/","title":{"rendered":"L\u2019autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"367\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png\" alt=\"Older couple relaxing on a sofa beside text promoting the first-line combination therapy Keytruda + Kisplyx\" class=\"wp-image-67174\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png 1200w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png?resize=300,92 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png?resize=768,235 768w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png?resize=1024,313 1024w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png?resize=320,98 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/11\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_L.png?resize=120,37 120w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading has-positive-3-font-size has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--cd1327a764e5a4e03ee80d14cc2dbd3d\"><mark style=\"background-color:#ffffff\" class=\"has-inline-color has-teal-color\">Swissmedic a accord\u00e9 une nouvelle autorisation pour KEYTRUDA\u00ae (pembrolizumab) plus KISPLYX\u00ae (lenvatinib).<sup>1,2<\/sup><\/mark><\/h3>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a12abd2ed2d93202a82418477bb54db9\">Le pembrolizumab, traitement d\u2019immunoth\u00e9rapie de MSD, est autoris\u00e9 d\u00e8s \u00e0 pr\u00e9sent en association avec le lenvatinib, inhibiteur de la tyrosine-kinase d\u2019Eisai*, pour <strong>le traitement de premi\u00e8re ligne du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique)<\/strong> chez l\u2019adulte pr\u00e9sentant un profil de risque interm\u00e9diaire\/d\u00e9favorable.<sup>1,2<\/sup> Cette association est recommand\u00e9e comme traitement de premi\u00e8re ligne dans les guidelines de l\u2019ESMO, de l\u2019EAU et du NCCN.<sup>3-5<\/sup><\/p>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a560612121d595b70755dee9a2a07a51\">L\u2019autorisation est bas\u00e9e sur les r\u00e9sultats de l\u2019\u00e9tude KEYNOTE-581\/CLEAR.<sup>6-8<\/sup><\/p>\n\n\n\n<p class=\"has-positive-1-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--54c0aa313bb4cca255f2606bff16ba13\"><strong>Les avantages avec le KEYTRUDA\u00ae + KISPLYX\u00ae par rapport au sunitinib pour les patients \u00e0 profil de risque IMDC interm\u00e9diaire ou p\u00e9joratif:<sup>6<\/sup><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--7985d6dca993c4a35ba6b9baa141c694 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"fr-FR\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    PFS: HR = 0.36<sup>6<\/sup>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    ORR: 72.4 % vs. 28.8 %<sup>6<\/sup>; CR: 14.0 % vs. 3.9 %<sup>6<\/sup>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    OS: HR = 0.58<sup>6,*<\/sup>    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-negative-1-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--0eeb4a56eb9e02d87554f6aa14e14501\"><em>Crit\u00e8resd\u2019\u00e9valuation principal,:PFS; crit\u00e8res d&rsquo;\u00e9valuation secondaires,:ORR et OS.<br>KEYTRUDA\u00ae+KISPLYX\u00ae a donn\u00e9 un profil de s\u00e9curit\u00e9 g\u00e9rable, correspondant aux profils connus de chacun des deux m\u00e9dicaments.<br>Des \u00e9v\u00e9nements ind\u00e9sirables de tout grade ont n\u00e9cessit\u00e9 une r\u00e9duction de la dose de KISPLYX\u00ae chez 68,8\u00a0% et une r\u00e9duction de la dose de sunitinib chez 50,3\u00a0%. <br><\/em><\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--b4b0bfaceb42ed0f81d2840937841fcd\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--463141a1550626e774278b9ebd759702 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/rcc\/kn581-clear\/\" target=\"_self\" aria-label=\"Indication Keytruda : carcinome \u00e0 cellules r\u00e9nales (KN581 Clear)\">\n                    <span class=\"mhh-mcn-v1-link__label\">En savoir plus sur KEYNOTE-581<\/span>\n                <\/a><\/div>\n\n\n\n<p class=\"has-negative-1-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--cbf5c7647fa0f76aa529c946d842fe09\"><mark style=\"background-color:#ffffff\" class=\"has-inline-color\">*L&rsquo;OS m\u00e9diane n&rsquo;a pas \u00e9t\u00e9 atteinte dans les deux groupes. Le score de risque IMDC n&rsquo;a pas pu \u00eatre \u00e9valu\u00e9 pour n = 2 et n = 4 patients dans les bras de traitement KEYTRUDA\u00ae + KISPLYX\u00ae et sunitinib, respectivement. L&rsquo;\u00e9tude KEYNOTE-581\/CLEAR n&rsquo;a pas \u00e9t\u00e9 con\u00e7ue pour identifier des diff\u00e9rences dans l&rsquo;efficacit\u00e9 du traitement d&rsquo;\u00e9tude dans les diff\u00e9rents sous-groupes. En raison du faible nombre de patients et des d\u00e9s\u00e9quilibres possibles des caract\u00e9ristiques de base dans les sous-groupes, les r\u00e9sultats de l&rsquo;analyse exploratoire doivent \u00eatre interpr\u00e9t\u00e9s avec prudence. Dans l&rsquo;\u00e9tude clinique KEYNOTE-581\/CLEAR, les patients de tous les groupes de risque IMDC (favorable, interm\u00e9diaire et d\u00e9favorable) ont \u00e9t\u00e9 inclus. Pour le traitement de premi\u00e8re ligne du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9, le traitement d&rsquo;association KEYTRUDA\u00ae et KISPLYX\u00ae n&rsquo;est autoris\u00e9 en Suisse que pour les patients pr\u00e9sentant un profil de risque interm\u00e9diaire\/d\u00e9favorable.<\/mark><\/p>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\r\n<div class=\"inpsyde-iframe is-responsive has-transparent-background-color\">\r\n    <iframe loading=\"lazy\" height=\"400\" referrerpolicy=\"no-referrer-when-downgrade\" title=\"Ce contenu vous a-t-il \u00e9t\u00e9 pertinent ?\" src=\"https:\/\/go.screver.com\/msd-ch-cx\/newsroom-articles?lang=fr&amp;hideHeader=true\" width=\"100%\"><\/iframe>\r\n<\/div>\n\n\n<nav class=\"wp-block-mconnect-theme-related-content has-background has-light-grey-background-color\">\n\t<div class=\"wp-block-mconnect-theme-related-content__container\">\n\t\t\t\t\t<h3 class=\"wp-block-mconnect-theme-related-content__title\">\n\t\t\t\tContenu connexe\t\t\t<\/h3>\n\t\t\n\t\t\t\t\t<ul class=\"is-grid-layout has-columns has-three-columns has-top-vertical-alignment\">\n\t\t\t\t\n\n\n\n\n\n\t\t\t\t\t\t<li class=\"grid-item\">\n\t\t\t\t\t\t\t<article\n    class=\"content-item content-item-type-post is-display-media-style has-featured-image has-background has-white-background-color has-link post-102292 post type-post status-publish format-standard has-post-thumbnail hentry category-onco-news tag-cetec tag-congress-update tag-keytruda tag-melanome-2 tag-nsclc\">\n\t\t\t<div class=\"content-item__media-container\">\n\t\t\t<div class=\"content-media\">\n\t\t\t\t<div class=\"content-media__inner\">\n\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"635\" height=\"475\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?w=635&amp;h=475&amp;crop=1\" class=\"content-media__image\" alt=\"Image: ESMO 2025\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg 1536w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=300,224 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=768,575 768w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=1024,766 1024w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=320,239 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=120,90 120w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=180,135 180w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=635,475 635w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/11\/Teaser-ESMO-2025.jpg?resize=1400,1047 1400w\" sizes=\"auto, (max-width: 635px) 100vw, 635px\" \/>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\n    \n    <div class=\"content-item__content-container\">\n\t\t<div class=\"content-item__content-body\">\n\t\t\t\t\t\t\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__primary-tag\"\n\t\t\t\t\ttitle=\"Cet article a \u00e9t\u00e9 \u00e9tiquet\u00e9 comme : Congress Update\"\n\t\t\t\t>\n\t\t\t\t\tCongress Update\t\t\t\t<\/span>\n\t\t\t\t\t\t<header class=\"content-item__header\">\n\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__content-type content-type  content-type--post\">\n\t\t\t\t\t<span class=\"content-type__icon\">\n                                            <\/span>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t<h2 class=\"content-item__title\" data-enterprise-id=\"currentHeader\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/follow-up-esmo-2025\/\"\n                            class=\"content-item__title-link\"\n                            target=\"_self\"\n                            rel=\"\"\n\t\t\t\t\t\t\t              >\n                            Suivi de l\u2019ESMO 2025                        <\/a>\n\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\t\t\t<\/header>\n\t\t\t\n                                            <div class=\"content-item__content-meta badge-container\">                                                                <div class=\"content-item__dates badge badge--flat badge--dates\">\n                                                        <span class=\"content-item__dates--start badge--dates__start\">\n                                novembre 18, 2025                            <\/span>\n                                                                                                        <\/div>\n                                                                            <\/div>\n                \t\t<\/div>\n\t\t<div class=\"content-item__content-footer\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n\n    <\/article>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t<\/div>\n<\/nav>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--574852217a5893e1817f16036a114ec2\" id=\"referenzen\"><mark style=\"background-color:#ffffff\" class=\"has-inline-color\"><strong><strong>R\u00e9f\u00e9rences<\/strong><\/strong>:<\/mark><\/h5>\n\n\n\n<ol class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--3c0f4a879eb10d301245af8a6152c56f mhh-mcn-list mhh-mcn-v2-clist--ordered mhh-mcn-v2-clist--ordered-decimal\" dir=\"ltr\" lang=\"fr-FR\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Information professionnelle KEYTRUDA\u00ae (pembrolizumab), https:\/\/www.swissmedicinfo.ch.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Information professionnelle KISPLYX\u00ae (lenvatinib), https:\/\/www.swissmedicinfo.ch.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <mark style=\"background-color:#ffffff\" class=\"has-inline-color\">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Kidney Cancer V4.2022. http:\/\/www.nccn.org.<\/mark>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <mark style=\"background-color:#ffffff\" class=\"has-inline-color\">Ljungberg B et al. EAU Guidelines on Renal Cell Carcinoma. Update M\u00e4rz 2021 unter https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Renal-Cell-Carcinoma-2021.pdf.<\/mark>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <mark style=\"background-color:#ffffff\" class=\"has-inline-color\">Powles T, Albiges L, Bex A, Gr\u00fcnwald V, Porta C, Procopio G, Schmidinger M, Su\u00e1rez C, de Velasco G, on behalf of the ESMO Guidelines Committee, ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma, Annals of Oncology (2021), E-Update: https:\/\/www.esmo.org\/guidelines\/genitourinary-cancers\/renal-cell-carcinoma\/eupdate-renalcell-carcinoma-treatment-recommendations-4.<\/mark>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <mark style=\"background-color:#ffffff\" class=\"has-inline-color\">Gr\u00fcnwald V, Powles T, Kopyltsov A, et al. Analysis of the CLEAR Study in Patients With Advanced Renal Cell Carcinoma: Depth of Response and Efficacy for Selected Subgroups in the Lenvatinib-Plus-Pembrolizumab and Sunitinib Treatment Arms. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 4 \u2013 8, 2021; Virtual Format.<\/mark>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <mark style=\"background-color:#ffffff\" class=\"has-inline-color\">Motzer R, George S, Merchan J, et al. Characterization and Management of Adverse Reactions in Patients with Advance Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study). (Poster #CTR14) Presented at the International Kidney Cancer Symposium 2021; November 5 \u2013 6, 2021; Hybrid Format.<\/mark>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <mark style=\"background-color:#ffffff\" class=\"has-inline-color\">Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289 \u2013 1300.<\/mark>    <\/li>\n\n<\/ol>\n\n\n\n<p class=\"has-negative-1-font-size has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--dedef5b9daabc56b5f7b615d9d07c5e8\">En cas de besoin, des copies des publications d\u2019\u00e9tudes peuvent \u00eatre demand\u00e9es \u00e0 l\u2019adresse dpoc.switzerland@msd.com.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&amp;lang=FR&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener\">Information professionnelle KEYTRUDA\u00ae<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&amp;lang=FR&amp;authNr=66085&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener\">Information professionnelle KISPLYX\u00ae<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Swissmedic a accord\u00e9 une nouvelle autorisation pour KEYTRUDA\u00ae (pembrolizumab) plus KISPLYX\u00ae (lenvatinib).1,2 Le pembrolizumab, traitement d\u2019immunoth\u00e9rapie de MSD, est autoris\u00e9 [&hellip;]<\/p>\n","protected":false},"author":427,"featured_media":67175,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","hide_featured_image":true,"primary_tag":842,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[792],"tags":[842],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[957],"ga4_page_businessunit":[963],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1206],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[627],"tx-product":[],"tx-pathology":[],"tx-content-type":[],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-55769","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-onco-news","tag-carcinome-a-cellules-renales"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L&#039;autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9. - MyMSD.ch FR Onco News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9. - MyMSD.ch FR Onco News\" \/>\n<meta property=\"og:description\" content=\"Swissmedic a accord\u00e9 une nouvelle autorisation pour KEYTRUDA\u00ae (pembrolizumab) plus KISPLYX\u00ae (lenvatinib).1,2 Le pembrolizumab, traitement d\u2019immunoth\u00e9rapie de MSD, est autoris\u00e9 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch FR\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-20T11:04:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-23T18:41:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png\" \/>\n\t<meta property=\"og:image:width\" content=\"635\" \/>\n\t<meta property=\"og:image:height\" content=\"475\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"michaelhuesler1\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"michaelhuesler1\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\"},\"author\":{\"name\":\"michaelhuesler1\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/0c7449d8e3dcf22b059331a9142e4dde\"},\"headline\":\"L\u2019autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9.\",\"datePublished\":\"2022-05-20T11:04:16+00:00\",\"dateModified\":\"2025-11-23T18:41:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\"},\"wordCount\":403,\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png\",\"keywords\":[\"Carcinome \u00e0 cellules r\u00e9nales\"],\"articleSection\":[\"Onco News\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\",\"name\":\"L'autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9. - MyMSD.ch FR Onco News\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png\",\"datePublished\":\"2022-05-20T11:04:16+00:00\",\"dateModified\":\"2025-11-23T18:41:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png\",\"width\":635,\"height\":475},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L\u2019autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"name\":\"MyMSD.ch FR\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/0c7449d8e3dcf22b059331a9142e4dde\",\"name\":\"michaelhuesler1\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a15aa52280d3c01526e7127aad7982d2c54f068dc5b17b406fb10311b6eff8ed?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a15aa52280d3c01526e7127aad7982d2c54f068dc5b17b406fb10311b6eff8ed?s=96&d=mm&r=g\",\"caption\":\"michaelhuesler1\"},\"url\":\"https:\/\/www.mymsd.ch\/fr\/author\/michaelhuesler1\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9. - MyMSD.ch FR Onco News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/","og_locale":"fr_FR","og_type":"article","og_title":"L'autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9. - MyMSD.ch FR Onco News","og_description":"Swissmedic a accord\u00e9 une nouvelle autorisation pour KEYTRUDA\u00ae (pembrolizumab) plus KISPLYX\u00ae (lenvatinib).1,2 Le pembrolizumab, traitement d\u2019immunoth\u00e9rapie de MSD, est autoris\u00e9 [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/","og_site_name":"MyMSD.ch FR","article_published_time":"2022-05-20T11:04:16+00:00","article_modified_time":"2025-11-23T18:41:57+00:00","og_image":[{"width":635,"height":475,"url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png","type":"image\/png"}],"author":"michaelhuesler1","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"michaelhuesler1","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#article","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/"},"author":{"name":"michaelhuesler1","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/0c7449d8e3dcf22b059331a9142e4dde"},"headline":"L\u2019autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9.","datePublished":"2022-05-20T11:04:16+00:00","dateModified":"2025-11-23T18:41:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/"},"wordCount":403,"publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png","keywords":["Carcinome \u00e0 cellules r\u00e9nales"],"articleSection":["Onco News"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/","url":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/","name":"L'autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9. - MyMSD.ch FR Onco News","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png","datePublished":"2022-05-20T11:04:16+00:00","dateModified":"2025-11-23T18:41:57+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#primaryimage","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/05\/L-autorisation-de-KEYTRUDA-plus-KISPLYX-pour-le-traitement_S.png","width":635,"height":475},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/fr\/oncology\/onco-news\/keytruda-plus-kisplyx-pour-le-traitement-du-carcinome-a-cellules-renales-avance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"L\u2019autorisation de KEYTRUDA\u00ae plus KISPLYX\u00ae pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9."}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/fr\/#website","url":"https:\/\/www.mymsd.ch\/fr\/","name":"MyMSD.ch FR","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/fr\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/0c7449d8e3dcf22b059331a9142e4dde","name":"michaelhuesler1","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a15aa52280d3c01526e7127aad7982d2c54f068dc5b17b406fb10311b6eff8ed?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a15aa52280d3c01526e7127aad7982d2c54f068dc5b17b406fb10311b6eff8ed?s=96&d=mm&r=g","caption":"michaelhuesler1"},"url":"https:\/\/www.mymsd.ch\/fr\/author\/michaelhuesler1\/"}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts\/55769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/users\/427"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/comments?post=55769"}],"version-history":[{"count":16,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts\/55769\/revisions"}],"predecessor-version":[{"id":102537,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/posts\/55769\/revisions\/102537"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media\/67175"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media?parent=55769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/categories?post=55769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tags?post=55769"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_audience?post=55769"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_birn_id?post=55769"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_branding?post=55769"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_businessunit?post=55769"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_campaign?post=55769"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=55769"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=55769"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=55769"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_experience?post=55769"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_indication?post=55769"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_material_intent?post=55769"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_product?post=55769"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_region?post=55769"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=55769"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-therapeutic-area?post=55769"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-product?post=55769"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-pathology?post=55769"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-content-type?post=55769"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-active-ingredient?post=55769"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/access?post=55769"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_status?post=55769"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_role?post=55769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}